MX2017013687A - Polipeptidos dirigidos a la fusion de vih. - Google Patents

Polipeptidos dirigidos a la fusion de vih.

Info

Publication number
MX2017013687A
MX2017013687A MX2017013687A MX2017013687A MX2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A
Authority
MX
Mexico
Prior art keywords
hiv fusion
polypeptides
targeting hiv
polypeptides targeting
fibronectin
Prior art date
Application number
MX2017013687A
Other languages
English (en)
Inventor
Davis Jonathan
R Krystal Mark
L Wensel David
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MX2017013687A publication Critical patent/MX2017013687A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)

Abstract

La invención se refiere a polipóptidos que comprenden una porción de fijación a CD4, una porción de fijación a gp41, una porción inhibidora peptí­dica de la fusión de VIH y combinaciones de estas. Más especí­ficamente, la presente invención se refiere a polipóptidos que comprenden una proteí­na del dominio de andamiaje a base de fibronectina que se fija a CD4, una proteí­na del dominio de andamiaje a base de fibronectina que se fija al dominio N17 de gp41 y un inhibidor peptí­dico de la fusión de VIH, o combinaciones de estos. La invención también se refiere al uso de las proteí­nas innovadoras en aplicaciones terapéuticas para tratar el VIH.
MX2017013687A 2015-04-24 2016-04-14 Polipeptidos dirigidos a la fusion de vih. MX2017013687A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US201562257474P 2015-11-19 2015-11-19
PCT/US2016/027424 WO2016171980A1 (en) 2015-04-24 2016-04-14 Polypeptides targeting hiv fusion

Publications (1)

Publication Number Publication Date
MX2017013687A true MX2017013687A (es) 2018-07-06

Family

ID=55809237

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013687A MX2017013687A (es) 2015-04-24 2016-04-14 Polipeptidos dirigidos a la fusion de vih.

Country Status (25)

Country Link
US (2) US10407490B2 (es)
EP (2) EP3985020A1 (es)
JP (3) JP6894846B2 (es)
KR (1) KR20170138558A (es)
CN (1) CN107922474A (es)
AU (2) AU2016252008B2 (es)
BR (1) BR112017022790A2 (es)
CA (1) CA2983276A1 (es)
CL (1) CL2017002687A1 (es)
CO (1) CO2017011583A2 (es)
CR (1) CR20170482A (es)
DO (1) DOP2017000246A (es)
EA (1) EA035332B1 (es)
ES (1) ES2884267T3 (es)
HK (1) HK1243432A1 (es)
IL (1) IL255122A0 (es)
MA (2) MA56222A (es)
MX (1) MX2017013687A (es)
PE (1) PE20180162A1 (es)
PH (1) PH12017501914A1 (es)
PT (1) PT3286212T (es)
SG (1) SG11201708441RA (es)
TW (1) TW201643185A (es)
UY (1) UY36650A (es)
WO (1) WO2016171980A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑***和其靶向载运***
JP2021507717A (ja) * 2017-12-18 2021-02-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ 抗原結合性ポリペプチド
CN108997482A (zh) * 2018-08-09 2018-12-14 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2021081515A2 (en) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
CN117980465A (zh) * 2021-08-30 2024-05-03 康霖生物科技（杭州）有限公司 一种用于艾滋病病毒感染基因治疗的基因序列构建体

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP3692542B2 (ja) 1997-01-21 2005-09-07 ザ ジェネラル ホスピタル コーポレーション Ｒｎａ−蛋白質の融合体を用いた蛋白質の選抜
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU2001277867B2 (en) 2000-07-11 2006-12-07 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
MXPA05002851A (es) * 2002-09-27 2005-09-08 Tanox Inc Composiciones sinergicas para la prevencion y el tratamiento del sindrome de inmunodeficiencia adquirida.
ES2551682T3 (es) 2002-11-08 2015-11-23 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20090022720A1 (en) * 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
ES2620285T3 (es) 2008-05-02 2017-06-28 Novartis Ag Moléculas de unión con base en fibronectina mejorada y usos de las mismas
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition
EP3424949A1 (en) * 2010-04-13 2019-01-09 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
MX2012012736A (es) * 2010-05-07 2013-02-26 Hoffmann La Roche Metodo de diagnostico para la deteccion de celulas ex vivo.
CN103380143B (zh) 2010-12-22 2016-01-06 百时美施贵宝公司 结合il-23的基于纤连蛋白的支架结构域蛋白质
CA2834577A1 (en) 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
EP4151785A1 (en) 2011-09-27 2023-03-22 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
WO2014120891A2 (en) * 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US20160152686A1 (en) * 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
CN103333255A (zh) 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Also Published As

Publication number Publication date
BR112017022790A2 (pt) 2018-07-17
EP3985020A1 (en) 2022-04-20
US10407490B2 (en) 2019-09-10
TW201643185A (zh) 2016-12-16
SG11201708441RA (en) 2017-11-29
EP3286212B1 (en) 2021-06-02
MA56222A (fr) 2022-04-20
HK1243432A1 (zh) 2018-07-13
CN107922474A (zh) 2018-04-17
JP7465378B2 (ja) 2024-04-10
EP3286212A1 (en) 2018-02-28
WO2016171980A1 (en) 2016-10-27
JP2018516247A (ja) 2018-06-21
PT3286212T (pt) 2021-08-24
PE20180162A1 (es) 2018-01-18
DOP2017000246A (es) 2018-01-31
AU2019226255A1 (en) 2019-09-26
AU2016252008A1 (en) 2017-11-09
EA035332B1 (ru) 2020-05-28
CA2983276A1 (en) 2016-10-27
JP2021035951A (ja) 2021-03-04
PH12017501914A1 (en) 2018-03-05
JP2023055875A (ja) 2023-04-18
CL2017002687A1 (es) 2018-04-20
KR20170138558A (ko) 2017-12-15
US11155602B2 (en) 2021-10-26
ES2884267T3 (es) 2021-12-10
IL255122A0 (en) 2017-12-31
CO2017011583A2 (es) 2018-04-19
US20190359688A1 (en) 2019-11-28
CR20170482A (es) 2018-03-07
AU2016252008B2 (en) 2019-06-13
US20180111980A1 (en) 2018-04-26
JP6894846B2 (ja) 2021-06-30
MA41943A (fr) 2018-02-28
EA201792269A1 (ru) 2018-04-30
UY36650A (es) 2016-11-30

Similar Documents

Publication Publication Date Title
PH12017501914A1 (en) Polypeptides targeting hiv fusion
MX2022014631A (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih.
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
EP4230627A3 (en) Inhibitors of the menin-mll interaction
GB2578802B (en) Programmable DNA binding proteins that increase efficiency and/or specificity of genome targeting in eukaryotic cells for use in therapy
PH12021500001A1 (en) Antibodies that target hiv gp120 and methods of use
WO2015109124A3 (en) Immunomodulatory agents
MX2021003475A (es) Metodos de purificacion de proteinas.
WO2018191548A3 (en) Complement factor d antagonist antibodies and conjugates thereof
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
WO2018057967A3 (en) Constructs targeting hiv peptide/mhc complexes and uses thereof
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
PH12018500645A1 (en) Hiv antibody compositions and methods of use
AR104390A1 (es) Polipéptidos dirigidos a la fusión de vih
TN2018000137A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EA201991733A1 (ru) Фармацевтические композиции для комбинированной терапии
EA201992151A1 (ru) Фармацевтические композиции для комбинированной терапии
WO2015134854A3 (en) Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics